BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition at the company. The ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine ...

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary ...

Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latestAdvanced ...

German vaccine maker BioNTech significantly lowered its full year sales outlook range on Tuesday due to softer-than-expected ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

European regulators have officially approved the latest 2026–2027 COVID-19 vaccine formula from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Designed to protect against the widespread XFG ...

Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.

Q2 2026 earnings call recap: guidance cut, CEO transition, oncology pipeline updates, and key catalysts—read insights and what’s next.

Here’s what we’ve learned – and how our understanding has evolved – since the earliest cases of the novel coronavirus were ...

Aug 3 (Reuters) - German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive. Oelkers will take on the role from February 1, 2027 at ...